An open map of which cancer proteins any drug can stick to

Activity-based protein profiling with covalent fragment libraries can measure ligandable sites across thousands of proteins in cancer cell lysates and live cells. Existing datasets are partial and largely proprietary. A precompetitive atlas covering the cysteine, lysine and tyrosine proteomes across 50 cancer models, published openly with hit compounds deposited, would convert 'undruggable' from an assertion into a measurement.